Valeant Pharma's (VRX) Proposed Credit Amendment Will Improve Liquidity Position - Moody's
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Big Valeant Pharma (VRX) Investors, Pershing Square's Ackman Met Ahead of Q2 Report -NYP
August 10, 2016 10:01 AM EDTLarge Valeant Pharmaceuticals (NYSE: VRX) investors were said to have met up with Pershing Square's Bill Ackman weeks before the company's Q2 release, which had it announce plans to reorganize and pay-down debt, according to the NYPost.
BofA... More
BTIG Remains Neutral on Valeant (VRX) Post-Q2; Sees Longer-than-Projected Path to Recovery
August 10, 2016 9:54 AM EDTBTIG affirms Valeant Phama (NYSE: VRX) at Neutral following Q2 results from the company.
Analyst Timothy Chiang commented, While quarterly results were mixed, the Co. maintained its full year financial targets (which include revenues of $9.9 - $10.1B and EPS of $6.60 - $7.00). While... More
Valeant (VRX) PT Bumped to $22 at Piper Jaffray; Keeps Lowest Rating
August 10, 2016 7:04 AM EDTPiper Jaffray analyst David Amsellem bumped his price target on Valeant Pharmaceuticals (NYSE: VRX) to $22.00 (from $19.00) but maintained an Underweight rating following results and reaffirmed guidance, which the analyst said may be overly optimistic.
Amsellem commented, "Valeant reported 2Q16 non-GAAP diluted EPS of $1.40 on revenue of $2.42B, lighter than Street... More
